Close Menu

herpes

By a GenomeWeb staff reporter


NEW YORK (GenomeWeb News) – BioHelix today announced that the US Food and Drug Administration has given 510(k) clearance for its assay for the detection of herpes simplex virus.

Medical Diagnostic Lab has been awarded US Patent No. 8,030,032, "Methods and compositions related thereto for detecting and identifying distinct species of nucleic acids from causative agents."

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – EraGen Biosciences today announced the US Food and Drug Administration has cleared its MultiCode-RTx HSV 1&2 kit for use on bioMérieux's NucliSens easyMag extraction system.

Akonni will use the grant to develop a closed amplicon RT-PCR microarray for detecting enterovirus, herpes viruses, and West Nile virus in cerebral spinal fluid.

In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.

BioMérieux plans to migrate Argene's test products onto a molecular diagnostic platform it is co-developing with Biocartis.

According to BD, the BD ProbeTec Herpes Simplex Viruses Qx Amplified DNA Assays are the first automated molecular assays for the detection and differentiation of HSV types 1 and 2 in clinician-collected external anogenital specimens.

The BD ProbeTec HSV-1 and HSV-2 Qx Amplified DNA assays are the first fully automated molecular tests for HSV types 1 and 2.

Pages

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.